Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MLYCD | O95822 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307956 | 0.79 | HCAR2 (0.50) | KDM4EKMT2AMLYCDHTTHSD17B10 | |
| SCHEMBL28777 | 0.79 | MLYCD (0.54) | KDM4EKMT2AMLYCDLMNANAPRT | |
| SCHEMBL353139 | 0.79 | KDM4E (0.60) | KDM4EKMT2AMLYCDLMNAHTT | |
| SCHEMBL434252 | 0.78 | ALDH1A1 (0.59) | KDM4EKMT2AMLYCDHTTCYP1A2 | |
| SCHEMBL22531823 | 0.78 | MLYCD (0.57) | KDM4EKMT2AMLYCDPOLBSMN1; SMN2 | |
| SCHEMBL1012521 | 0.78 | MLYCD (0.57) | KDM4EKMT2AMLYCDLMNAPOLB | |
| Hydrochloric Acid SCHEMBL7476159 | 0.78 | MLYCD (0.53) | KDM4EKMT2AMLYCDLMNANAPRT | |
| SCHEMBL870352 | 0.78 | MLYCD (0.57) | KMT2AMLYCDLMNAHTTSMN1; SMN2 | |
| SCHEMBL1303906 | 0.78 | MLYCD (0.57) | KMT2AMLYCDLMNAHTTSMN1; SMN2 | |
| SCHEMBL2507311 | 0.78 | HCAR2 (0.46) | KDM4EKMT2AMLYCDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4472974-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHROEDINGER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101549-A1 | 2-ANILINO-4-(IMIDAZOL-5-YL)-PYRIMIDINE DERIVATIVES AND THEIR USE AS CDK (CDK2) INHIBITORS | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. | 2004-10-21 | — | — | US | disclosed |
| US-6713627-B2 | FOR RECEPTOR ANTAGONISTS IN TREATMENT OF SCHIZOLPHRENIA, ANXIETY, VARIANT ANGINA, ANOREXIA VERVOSA, RAYNAUD'S PHENOMENON, INTERMITTENT CLAUDICATION, CORONARY OR PERIPHERAL VASOSPASMS, FIBROMYALGIA, CARDIAC ARRHYTHMIA'S, AND THROMBOSIS | AVENTIS PHARMACEUTICALS INC. | 2004-03-30 | — | — | US | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTISUB II INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | KDM4E 2609/4885KMT2A 1401/4885MLYCD 286/4885 |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CBR1 | KDM4E 1566/4885KMT2A 2927/4885MLYCD 1181/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | KDM4E 4187/4885KMT2A 4685/4885MLYCD 1650/4885 |
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | KDM4E 4187/4885KMT2A 4685/4885MLYCD 1650/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | KDM4E 217/4885KMT2A 245/4885MLYCD 3573/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | KDM4E 3799/4885KMT2A 4473/4885MLYCD 4858/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | KDM4E 2609/4885KMT2A 1401/4885MLYCD 286/4885 |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CYP1A1 | KDM4E 1551/4885KMT2A 2996/4885MLYCD 944/4885 |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | KDM4E 1289/4885KMT2A 2559/4885MLYCD 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.